Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16893617 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL29768587 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL19097649 | 0.91 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL19097650 | 0.91 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL16893788 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL16893786 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL22540724 | 0.86 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL20921364 | 0.86 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL20646313 | 0.86 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL20646289 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | claimed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | claimed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | claimed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | claimed |
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10414744-B2 | 4-sulfur pentafluoride phenol compound and preparation method therefor, and preparation method for sulfur pentafluoride substituted benzopyran compound | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences (CN) | 2019-09-17 | — | — | US | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190084957-A1 | 4-SULFUR PENTAFLUORIDE PHENOL COMPOUND AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR SULFUR PENTAFLUORIDE SUBSTITUTED BENZOPYRAN COMPOUND | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences (CN) | 2019-03-21 | — | — | US | disclosed |
| EP-3428154-A1 | 4-SULFUR PENTAFLUORIDE PHENOL COMPOUND AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR SULFUR PENTAFLUORIDE SUBSTITUTED BENZOPYRAN COMPOUND | Guangzhou Institutes Of Biomedicine And Health Chinese Academy Of Sciences (CN) | 2019-01-16 | — | — | EP | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| CN-106102747-A | NO-releasing nitrooxy-chromene conjugates | 欧利瑟斯制药公司 | 2016-11-09 | — | — | CN | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | ARG1, ARGLU1, CGAS | PTGS2 1336/4885PTGS1 901/4885 |
| US-20190084957-A1 | 4-SULFUR PENTAFLUORIDE PHENOL COMPOUND AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR SULFUR PENTAFLUORIDE SUBSTITUTED BENZOPYRAN COMPOUND | SALL4, FGFR4, CYP4F11 | PTGS2 2383/4885PTGS1 2136/4885 |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
| US-10414744-B2 | 4-sulfur pentafluoride phenol compound and preparation method therefor, and preparation method for sulfur pentafluoride substituted benzopyran compound | SALL4, FGFR4, CYP4F11 | PTGS2 2383/4885PTGS1 2136/4885 |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | CD274, ICOS, PDCD1 | PTGS2 3149/4885PTGS1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.